Genitourinary Cancer Trial
Bladder Cancer, Node Positive
Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)
EA8185 represents a joint scientific collaboration between ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and NRG Oncology, with ECOG-ACRIN as the lead group for trial conduct.
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Information and Assistance from the National Cancer Institute
- Locations and other information
- Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.
ClinicalTrials.gov ID: NCT04216290
Return to Home Page | Review Other Active Trials